{
  "id": 7087284,
  "title": "BridgeBio Oncology Therapeutics (BBOT) Bets Big On A Narrower KRAS Playbook",
  "url": "https://urgent.news/2026/09/12/bridgebio-oncology-therapeutics-bbot-bets-big-on-a-narrower-kras",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-12T07:40:39.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/healthcare/articles/bridgebio-oncology-therapeutics-bbot-bets-074039253.html"
  },
  "original_language": "en",
  "account": "On September 8, BridgeBio Oncology Therapeutics (NASDAQ:BBOT) unveiled fresh clinical data for its lead KRASG12C inhibitor, BBO-8520. Leveraging this opportunity, the company decided to narrow its focus on BBO-8520 in combination with checkpoint inhibitors for patients with previously treated lung cancer, alongside ongoing combination studies for its two earlier-stage assets, BBO-11818 and BBO-10203, targeting other KRAS-mutant tumors. This strategic shift reflects BridgeBio's belief in where its investments can make the most impact. A key figure from the September 8 release is a 75% objective response rate when BBO-8520 was combined with pembrolizumab in patients whose lung cancer had progressed on a prior G12C inhibitor, with a 53% response rate across all tested doses. Lung cancer patients with the KRAS G12C mutation, estimated to be around 21,000 in the US in 2026, have no approved targeted therapy once a first G12C drug stops working, and BridgeBio anticipates this pool will expand as newer inhibitors move earlier into treatment. BBO-8520 monotherapy also showed promise in patients who had never taken a G12C inhibitor, with a 63% response rate, and no patients experienced grade 3 liver enzyme elevations, a common side effect in this class of drugs. At June 30, the company had $344.1 million in cash, which is expected to fund operations until 2028, allowing management to concentrate capital on promising combination strategies, including internal trials involving BBO-11818 and BBO-10203. However, the early-stage data is still pending, with the most validating data for the strategic pivot - the expanded 8520-pembrolizumab dataset and combination results in colorectal and pancreatic cancer - not expected until mid-2027. Currently, short interest stands at 21.69% of the float, indicating organized skepticism about the early-phase response rates' durability in larger trials. While BridgeBio is betting on a 75% response rate in a patient population with no other options, the company is also burning cash at a faster rate than a year ago. For potential investors, this presents a dual risk-reward scenario, requiring confirmation of early-phase results by larger trials to validate the company's strategic shift.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}